ArticleExperimental and therapeutic medicine2019
The risk factors of portal vein thrombosis in patients with liver cirrhosis.
Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- [Efficacy evaluation of novel oral anticoagulants in patients with cirrhosis accompanied with portal vein thrombosis: a meta-analysis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Pooled it
- Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta-Blockers: A Multi-Institutional Cohort Study.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Portal Vein Thrombosis in Liver Cirrhosis: A Review of Risk Factors and Predictive Indicators.Journal of clinical and translational hepatology · 2025Review
- Construction of a Nomogram for Portal Vein Thrombosis After Endoscopic Therapy of Severe Gastroesophageal Varices in Cirrhotic Patients.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Analysis of related factors of portal vein thrombosis in liver cirrhosis.BMC gastroenterology · 2023Article
- Nomogram for Predicting Portal Vein Thrombosis in Cirrhotic Patients: A Retrospective Cohort Study.Journal of personalized medicine · 2023Article
- Portal Vein Thrombosis in the Setting of Cirrhosis: A Comprehensive Review.Journal of clinical medicine · 2022Review
- Increased portal vein diameter is predictive of portal vein thrombosis development in patients with liver cirrhosis.Annals of translational medicine · 2021Article
- Portal Thrombosis in Cirrhosis: Role of Thrombophilic Disorders.Journal of clinical medicine · 2020Article
- Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.JHEP reports : innovation in hepatology · 2020Article
- Portal vein thrombosis secondary to postoperative gastric cancer: Report of two cases.The Journal of international medical research · 2020Article
- [Research progress of cirrhosis with portal vein thrombosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was designed to identify and assess risk factors for portal vein thrombosis (PVT) in patients with cirrhosis. A total of 98 cirrhosis patients with PVT were identified and 101 cirrhosis patients without PVT were chosen as the control group in this retrospective study. Several variables were measured and the two groups PVT and non-PVT were compared statistically. PVT was identified in 98 patients (10%). Significant differences in hematocrit, international normalized ratio, albumin, bilirubin and glucose were determined between the groups (P<0.05). Out of the thrombophilic risk factors in the patients with PVT factor V Leiden was identified in 8.8%, prothrombin gene 6.6% and methylenetetrahydrofolate reductase 2.2%. There was no difference in survival time between groups (P>0.05).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.